GRI Bio (GRI) Expected to Release Quarterly Earnings on Friday

GRI Bio (NASDAQ:GRI) is expected to be issuing its Q3 2026 results on Friday, November 13th. Analysts expect the company to post earnings of ($0.84) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

GRI Bio (NASDAQ:GRI) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.19) by $0.28. On average, analysts expect GRI Bio to post ($3.75) EPS for the current fiscal year and ($2.00) EPS for the next fiscal year.

GRI Bio Stock Performance

NASDAQ:GRI opened at $1.87 on Thursday. GRI Bio has a 52-week low of $1.36 and a 52-week high of $64.12. The stock’s 50 day moving average price is $1.78 and its 200 day moving average price is $2.10.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating on shares of GRI Bio in a report on Tuesday, October 13th. Weiss Ratings restated a “sell (e+)” rating on shares of GRI Bio in a research report on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $21.00.

About GRI Bio

GRI Bio, Inc. (NASDAQ: GRI) is a clinical-stage biotechnology company focused on developing therapies that modulate natural killer T (NKT) cells. NKT cells are immune cells involved in regulating inflammation and immune responses, and the company is researching their potential role in autoimmune, inflammatory, and fibrotic diseases. GRI Bio’s lead product candidate is GRI-0621, an orally administered small-molecule inhibitor designed to selectively modulate type I NKT cells. The company has been evaluating GRI-0621 as a potential treatment for idiopathic pulmonary fibrosis, a progressive lung disease characterized by scarring and impaired respiratory function.